Friday 6 November 2026 Export EXEL’s income statement to Excel — free account

Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue: +10.2%
EPS: +22.2%
Free cash flow: −4.83%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

69.76 1.05 +1.53%

Follow EXEL

Alert me

Market cap: $16.8B
P/E: 19.9×
Fwd P/E: 20.2×
Dividend yield: —
F-score: 7/9
Altman Z: 12.68
Beneish M: −2.61
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Exelixis, Inc. (EXEL) revenue by segment, product and region

	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023
CABOMETYX	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Collaboration	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
COMETRIQ	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Gross product revenues	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
License revenues	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Collaboration services revenues	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Discounts and allowances	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Collaboration, Research And Development Service	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Collaboration, Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Net product revenues	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Exelixis, Inc. (EXEL) revenue by segment, product and region

Stockrow Weekly